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PTFE Valved Conduits for RVPA Reconstruction:  
Do They Outperform Xenografts and Allografts? 
Doctor Miyazaki, Professor Yamagishi and colleagues are to be commended for their excellent PTFE 
valved RV-PA conduit clinical results, which are illustrated in this manuscript. 
Allografts and bovine jugular vein conduits have been the most popular RVPA conduits in the US and 
Europe for the last 2 decades. These conduits function well for a few years and their durability has 
improved.  Their limited long-term durability, however, necessitates multiple conduit exchanges over 
the patient’s lifetime.  Allografts are generally not available in Japan, and the bovine jugular vein conduit 
has only become available in the last 2-3 years.  Japan’s need for a RVOT reconstruction material 
stimulated their early interest in PTFE as a pulmonary valve substitute. 
Professor Yamagishi  first demonstrated the use of 0.1mm PTFE material (designed and developed for 
pericardial closure for making a synthetic pulmonary valve leaflet and published its use as a monocusp 
valve in 1993.  We adopted and modified the monocusp technique 24 years ago and continue to use it 
for pulmonary valve reconstruction in patients requiring a transannular patch.  Soon after their 
monocusp experience, Miyazaki & Yamagishi began making handmade conduits using 0.1mm PTFE for 
leaflets, and a thicker tubular PTFE for the conduit.  They recently added sinuses and fan-shaped leaflets 
since 2010 based on hydrodynamic experiments in a pulse duplicator. 
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This manuscript summarizes the outcomes of 902 patients with handmade PTFE valved conduits 
constructed by a single surgeon. The conduits included bulging sinuses and fan-shaped PTFE leaflets in 9 
different sizes (8-24mm in diameter) and were implanted in children and adults at 65 Japanese hospitals 
between 2001-2015.   The mean patient age was 3.9 years and mean weight was 12.5 kg. The patients 
had a variety of congenital cardiac malformations requiring RVOT reconstruction.  The patients’ hospital 
survival was excellent at 98%, and late survival was 95.5% out to 15 years.    
 
They compared patients by age greater or less than 2 years of age.  Those< 2 years of age (n=292) had a 
freedom from conduit replacement of 90% and 74% at 5 and 10 years, respectively.  Freedom from 
conduit replacement in the group older than 2 years was >95% at 10 years. 
 
Their conduits showed excellent freedom from infection, stenosis, and regurgitation (>95%) during 
follow-up (median=4.8 yrs.).  Fifty-five conduits (6%) were replaced mostly for outgrowth or stenosis 
proximal or distal to the valved conduit.  Fifty-three patients required balloon catheter intervention for 
proximal and/or distal stenosis.   
 
This large Japanese multicenter experience with a handmade conduit may not be immediately 
transferable to the US and Europe because the FDA and other governing bodies are not likely to approve 
handmade valved conduits due to inconsistent quality control.  The authors’ experience, however, is an 
excellent proof of concept and will open the door for industry to provide a consistent product for 
congenital heart surgeons.  
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PTFE valved conduits as shown in this manuscript show real promise as an alternative to currently 
available RVPA conduits.  Longer follow-up will be necessary to see if these conduits continue to 
perform as well as the authors report here.   
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